A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
12/2002
12/10/2002	US6492343 Porcine adenovirus type 3 genome
12/10/2002	US6492157 Methods are provided for the treatment of conditions associated with cells proliferation, cells differentiation and cell survival. in particular, the dual-specificity phosphatase dsp-9, and polypeptide variants thereof that
12/10/2002	US6492129 Fragments comprising the n-terminal region of connective tissue growth factor (ctgf); screening for inhibitors or stimulators of ctgf
12/10/2002	US6491943 Method for treating an allergic or inflammatory disease
12/10/2002	US6491926 35 kD tumor associated protein antigen: uses and methods of detection
12/10/2002	US6491920 Polypeptides and DNA encoding same
12/10/2002	US6491919 Attenuated lipid and surfactant in aqueous solution
12/10/2002	US6491915 Anti-CCR2 antibodies and methods of use therefor
12/10/2002	US6491914 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies
12/10/2002	CA2208792C Substituted indazole derivatives
12/10/2002	CA2196085C Mhc complexes and uses thereof
12/10/2002	CA2114015C Recombinant antibodies for human therapy
12/10/2002	CA2109934C Substituted indoles as anti-aids pharmaceuticals
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/07/2002	CA2386356A1 Ligation of ceacam1
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097094A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
12/05/2002	WO2002097070A1 Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097050A2 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
12/05/2002	WO2002097046A2 B7 related protein-2 molecules and uses thereof
12/05/2002	WO2002097044A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	WO2002097035A2 Secreted proteins
12/05/2002	WO2002097033A2 Antibodies that immunospecifically bind to trail receptors
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096952A2 Conjugate of a transport protein and a protein for modulation of notch signalling
12/05/2002	WO2002096951A1 Molecules for disease detection and treatment
12/05/2002	WO2002096949A1 Antigen targeting
12/05/2002	WO2002096943A1 Stat6-activating genes
12/05/2002	WO2002096942A2 Recombinant dna encoding the major allergen of plantago lanceolata pollen pla l 1, and applications thereof
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096926A1 Modulators of pharmacological agents
12/05/2002	WO2002096923A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
12/05/2002	WO2002096921A1 Novel glucose derivative inducing apoptosis, process for producing the same, and use thereof as medicine
12/05/2002	WO2002096909A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	WO2002096887A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096457A2 Stable liquid formulations of antibodies
12/05/2002	WO2002096455A2 Use of polyclonal immunoglobulins
12/05/2002	WO2002096447A2 Pharmaceutical preparation containing active ingredients extracted from the plants centella asiatica, mahonia aquifolium and viola tricolor
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein
12/05/2002	WO2002096386A1 Solid form immunity adjuvant and vaccine containing same
12/05/2002	WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	WO2002078720A3 Antibiotics from bacteria isolated from amphibian skin
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002064757A3 Influenza viruses with enhanced transcriptional and replicational capacities
12/05/2002	WO2002060924A9 Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding and development of a non-simian recombinant cell line for propagation of the virus and a target for a novel class of antiviral compounds
12/05/2002	WO2002059146A3 Peptides having affinity for the gp120 viral protein and use thereof
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002030985A3 Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
12/05/2002	WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002	WO2002020766A3 G-csf analog compositions and methods
12/05/2002	WO2002016413A3 Cripto tumour polypeptide
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002	WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002	WO2001088085A3 Novel bee venom polypeptides and methods of use thereof
12/05/2002	WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002	WO2001049743A9 Methods of modulation of the immune system
12/05/2002	WO2001034193A9 Plant lectins as mucosal adjuvants
12/05/2002	WO2001021796A9 Gl50 molecules and uses therefor
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183508 Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
12/05/2002	US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183360 Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels
12/05/2002	US20020183326 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them
12/05/2002	US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002	US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
12/05/2002	US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
12/05/2002	US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020182725 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/05/2002	US20020182703 Human defensin polypeptide Def-X, genomic DNA and cDNA, composition containing them and applications to diagnosis and to therapeutic treatment
12/05/2002	US20020182671 Polypeptide for use in the treatment, diagnosis, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gatrointestinal disorders
12/05/2002	US20020182650 Inhibitors of binding between proteins and macromolecular ligands
12/05/2002	US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect
12/05/2002	US20020182276 Morinda citrifolia (Noni) enhanced animal food product
12/05/2002	US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182221 Recombinant papillomavirus vaccine and method for production and treatment
12/05/2002	US20020182220 Isolating a heat shock protein 70- peptide complex from the mammal from tumor cells or cells infected with a virus, bacteria or infectious agent; and administering the heat shock protein peptide complex
12/05/2002	US20020182216 Eliciting a T-cell mediated immune response in an animal, comprising administering to the animal an extract of an egg comprising transfer factor generated by said source animal
12/05/2002	US20020182213 Method for the treatment of fibrosis

1 ... 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 ... 1172